tbuckley/cabot-search huggingface dataset:
Somatostatin Receptor Imaging:
Authors: NEIL KATZ, LAWRENCE A. GILBERT, JEFFREY T. WILLSEY
Journal: Clinical Nuclear Medicine (1997)

A 46-year-old man underwent neuroendocrine tumor imaging for a suspected pheochromocytoma using 5.8 mCi (215 MBq) In-111 pentetreotide injected intravenously. Laxatives were taken the evening before the injection and before the 24-hour images. Twenty-four hour planar and tomographic images showed increased activity in the region of the gallbladder fossa. To confirm that this was in the gallbladder and not a pathologic lesion, the patient ate a fatty meal consisting of two large hamburgers, french fries, and cookies. Anterior abdominal imaging performed afterwards showed clearing of activity, which indicates that the previously seen activity was within the gallbladder.
Teenage smoking is an "epidemic," says US surgeon general
Authors: J. H. Tanne
Journal: BMJ (2012)

Efforts to reduce smoking and other tobacco use by teenagers have stalled, and prevention should concentrate on teenagers because 99% of US smokers began smoking before they were 26, most in their teens, says a new report by the US surgeon general.

Regina Benjamin’s report is the first by a surgeon general since 1994 to report on young people’s tobacco use.

Over one million people begin to use tobacco products every year. Proved methods can prevent this epidemic claiming another generation, the report says, but they must be implemented in every state and community.

Kathleen Sebelius, secretary of health and human services, said in the report that every …
Risk Factors for Falls as a Cause of Hip Fracture in Women
Authors: Jeane Ann Grisso, Jennifer L. Kelsey, Brian L. Strom, Grace Y. Ghiu, Greg Maislin, Linda A. O'Brien, Susie Hoffman, Frederick Kaplan
Journal: New England Journal of Medicine (1991)

Although even in the elderly most falls are not associated with fractures, over 90 percent of hip fractures are the result of a fall. Few studies have assessed whether the risk factors for falls are also important risk factors for hip fracture.To examine the importance of risk factors for falls in the epidemiology of hip fracture, we performed a case-control study of 174 women (median age, 80 years) admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. Controls, matched to the case patients according to age and hospital, were selected from general surgical and orthopedic surgical hospital services. Information was obtained by direct interview.As measured by the odds ratio, increased risks for hip fracture were associated with lower-limb dysfunction (odds ratio = 1.7; 95 percent confidence interval, 1.1 to 2.8), visual impairment (odds ratio = 5.1; 95 percent confidence interval, 1.9 to 13.9), previous stroke (odds ratio = 2.0; 95 percent confidence interval, 1.0 to 4.0), Parkinson's disease (odds ratio = 9.4; 95 percent confidence interval, 1.2 to 76.1), and use of long-acting barbiturates (odds ratio = 5.2; 95 percent confidence interval, 0.6 to 45.0). Of the controls, 44 (25 percent) had had a recent fall. The case patients were more likely than these controls to have fallen from a standing height or higher (odds ratio = 2.4; 95 percent confidence interval, 1.0 to 5.7). Of those with hip fracture the younger patients (less than 75 years old) were more likely than the older ones (greater than or equal to 75 years old) to have fallen on a hard surface (odds ratio = 1.9; 95 percent confidence interval, 1.04 to 3.7).A number of factors that have been identified as risk factors for falls are also associated with hip fracture, including lower-limb dysfunction, neurologic conditions, barbiturate use, and visual impairment. Given the prevalence of these problems among the elderly, who are at highest risk, programs to prevent hip fracture should include measures to prevent falls in addition to measures to slow bone loss.
A Case for Venom Treatment in Anaphylactic Sensitivity to Hymenoptera Sting
Authors: Lawrence M. Lichtenstein, Martin D. Valentine, Anne K. Sobotka
Journal: New England Journal of Medicine (1974)

In a child of a beekeeping family anaphylaxis developed after a honey-bee sting. He was treated with the conventional therapy, whole-(insect)-body extracts, for nine months. A second sting caused anaphylaxis again. Since the patient's family history included a sister who had died in similar circumstances, he was immunized with 1.4 mg of honey-bee venom over a two-month period; the last two doses were 100 μg (≅ two bee stings). His sensitivity to venom, assessed by basophil histamine release, decreased, and his blocking (IgG) antibody level increased 300 times over that after immunization with whole-body extract. After venom immunization he tolerated a honey-bee sting without reaction. The case and a review of pertinent data suggest that venom immunization may be the treatment of choice for hymenoptera sensitivity. (N Engl J Med 290:1223–1227, 1974)
SAT0435 Profile and degree of hyperglycemia after the infiltration of intrarticular corticosteroids to patients with and without type 2 diabetes mellitus
Authors: P. Moya, A. Rodriguez de la Serna, B. Magallares, C. Diaz-Torné, M. Sarmiento, E. Cόrica, I. Castellví, C. Geli, A. Laiz, J. Malouf, A. Perez, J.M. de Llobet
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Corticosteroids (CS) are widely used in medicine for the treatment of multiple processes. In rheumatology, infiltrations with corticosteroids are indicated to relieve pain and improve joint limitation. Adverse effects of corticosteroids such as hyperglycemia are well known; nevertheless the existing information about the effects of the intrarticular administration is very scanty. <h3>Objectives</h3> The aim of this study was to define the profile and degree of hyperglycemia after intrarticular administration of triamcinolone acetonide to patients with and without type 2 diabetes. <h3>Methods</h3> It was an observational study. Twenty-one patients were included (9 with and 12 without type 2 diabetes). All of them received an intrarticular infiltration of 40 mg of triamcinolone acetonide and 1 ml of mepivacaine in a knee or a shoulder. All patients received a glucometer in order to determinate the glycemias before and 2 hours after breakfast, lunch and dinner, the previous day and during the 6 days after the procedure. A descriptive analysis, including demographic and clinical data, and a comparative analysis of mean glycemic data were performed. The results were analyzed using the SPSS's v19.0 statistical package. <h3>Results</h3> Patients without diabetes showed an increase of glycemic index 48 hours following the infiltration, whereas it wasn't observed in the diabetic patients. Likewise, we observed a statistically significant increase of the postprandial glycemia (167,36±58,39 vs 174,25±69,42mg/dl; p=0,025) of the day of the infiltration and in the determinations before breakfast (111,40±23,71 vs 135,77±62,26 mg/dl; p=0,008) and post lunch (152,089±25,9 vs 181±60,63 mg/dl; p=0,002) of the following day. <h3>Conclusions</h3> Type 2 diabetic patients do NOT need an increase of antidiabetic treatment after the intrarticular administration of 40 mg of acetone triamcinolone, provided that they do not present glycemic alterations after 6 days of the infiltration. On the other hand, the non-diabetic patients, present an hyperglycemic moderate and autolimited effect, without clinical significance. <h3>References</h3> Habib GS, Abu-Ahmad R. Lack of effect of corticosteroid injection at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol.2007;26:566–8. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717–20. <h3>Disclosure of Interest</h3> None Declared
Aspirin Prevention Update: New Data On Lung and Colon Cancers
Authors: C. Nelson
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Aspirin Prevention Update: New Data On Lung and Colon Cancers Get access Corinna Nelson Corinna Nelson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 8, 19 April 1995, Pages 567–569, https://doi.org/10.1093/jnci/87.8.567 Published: 19 April 1995
EXCESS EPICARDIAL ADIPOSE TISSUE IS ASSOCIATED WITH HIGH-RISK CORONARY PLAQUE ON CCTA INDEPENDENT OF RISK FACTORS, CORONARY CALCIUM SCORE AND STENOSIS: RESULTS FROM THE ROMICAT II TRIAL
Authors: Michael T. Lu, Jakob Park, Thomas Mayrhofer, Khristine Ghemigian, Stefan Puchner, Ting Liu, Jerome Fleg, James Udelson, Maros Ferencik, Udo Hoffmann
Journal: Journal of the American College of Cardiology (2015)
A NONINVASIVE HAND-HELD DEVICE IDENTIFIES ELEVATED LEFT VENTRICULAR FILLING PRESSURE USING FINGER PHOTOPLETHYSMOGRAPHY DURING THE VALSALVA MANEUVER
Authors: Panagis Galiatsatos, Theingi Win, Jennifer Monti, Peter Johnston, William Herzog, Jeffrey Trost, Chao-Wei Hwang, Nae-Yuh Wang, Harry Silber
Journal: Journal of the American College of Cardiology (2016)
PTH-265 Outcomes of redo rectopexy with and without resection for recurrent rectal prolapse: are the results comparable to the primary surgery?
Authors: Y Sato, G Dasilva, SD Wexner
Journal: Gut (2015)

<h3>Introduction</h3> The surgical approach to recurrent full-thickness rectal prolapse is more complicated than for primary full thickness rectal prolapse. However, it has not been reported that redo rectopexy for recurrent full thickness rectal prolapse is as safe and feasible as primary rectopexy. This study evaluated the safety and efficacy of redo rectopexy with and without resection for recurrent full thickness rectal prolapse. <h3>Method</h3> After IRB approval, 144 consecutive patients [138 females; mean age 57 (range, 16–83) years] with primary [n = 112; 108 females, mean age 56 (range, 16–80) years] or recurrent [n = 32; 30 females, mean age 58 (29–83) years] rectal prolapse who underwent rectopexy with and without resection between May 2000 and April 2014 were identified from a prospective database. Perioperative outcomes and reoperation rate due to recurrence were compared between the two groups. <h3>Results</h3> Both groups had comparable demographics, BMI, ASA scores, type of surgical approach, and comorbidities. Patients with primary rectopexy had a higher percentage of resected colon (60.7%) than did those with redo rectopexy (28.1%; <i>p = 0</i>.001). Patients had open (75 vs. 25), hand-assisted (3 vs. 1) and laparoscopic (34 vs. 6) surgery in the primary vs. redo rectopexy groups, respectively (p = 0.213). Intraoperative blood loss and length of postoperative stay were similar in both groups. The most common complication was ileus (n = 15). There was no significant difference in the postoperative complication rate (primary rectopexy 30.6% vs. redo rectopexy 37.5%; <i>p = 0</i>.521). The reoperation rate due to recurrence was significantly higher in redo rectopexy vs. primary rectopexy (12.5% vs. 1.8%; <i>p = 0</i>.022). The mean interval from primary surgery to reoperation for recurrence was 17.0 (range, 2.5–40.5) months for the redo rectopexy group and 46.8 (range, 30.0–63.7) months for the primary rectopexy. Functional data were not available. <h3>Conclusion</h3> Redo rectopexy with and without resection can be performed as safely as primary rectopexy in patients with full-thickness rectal prolapse. However, the re-reoperation rate due to recurrence of rectal prolapse is higher in redo rectopexy. <h3>Disclosure of interest</h3> None Declared.
TCTAP A-131 Correlation Between Traditional Cardiovascular Risk Factors and Complexity of Coronary Artery Lesion Determined by SYNTAX Score in Patient with ST-Elevation Myocardial Infarction
Authors: Intan Yustikasari, Toni Mustahsani Aprami, Pintoko Tedjokusumo, Augustine Purnomowati, Dwi Agustian
Journal: Journal of the American College of Cardiology (2015)
PMO-162 Pregnant mothers with chronic hepatitis B (HBV): how often is treatment needed?
Authors: J Dyson, E Michael, A Turley, S Moses, M Valappil, M Hudson, M Bassendine, S McPherson
Journal: Gut (2012)

<h3>Introduction</h3> HBV is a common cause of chronic liver disease worldwide. Vertical transmission is the commonest mode of infection. Since 2000 antenatal HBV screening is offered to all pregnant women in the UK. The British Viral Hepatitis Group recommend treating mothers with an HBV DNA level of &gt;10<sup>7</sup> IU/ml with antivirals in the 3rd trimester to reduce the transmission risk. Few studies have evaluated the epidemiology/management of pregnant patients with HBV in the UK. We reviewed the management of mothers with HBV attending our obstetric services. <h3>Methods</h3> Retrospective notes review of all HBV positive mothers who attended the obstetric service from January 07 to November 11. Data were collected on patient demographics, viral serology, HBV DNA and ALT levels and HBV management during their first pregnancy in the time period. <h3>Results</h3> 81 HBsAg positive mothers (median age 28, 18–44) had 113 pregnancies in the study period. 96% were referred to the viral hepatitis service; however 28% of women did not attend &gt;1 appointment. The mothers were born in 28 countries, most commonly China (30%) followed by countries in Eastern Europe (17%), Africa (16%), South Asia (16%) and elsewhere (21%). 29% were known to have chronic HBV (cHBV). All mothers were tested for HBeAg/Ab status: 15% were HBeAg positive, 85% HBeAg negative and 79% anti-HBe positive. 85% had HBV DNA checked during the pregnancy. 9% had active HBeAg positive cHBV (HBV DNA &gt;20 000 IU/ml, ALT &gt;40), 3% had active HBeAg negative cHBV (HBV DNA &gt;2000 and ALT &gt;40), 9% were immunotolerant (HBeAg positive, ALT &lt;40), 60% were inactive carriers (HBV DNA &lt;2000 and ALT &lt;40) and 19% were indeterminate. 13% of mothers had a HBV DNA &gt;10<sup>7</sup> IU/ml, but only two patients were treated with tenofovir in the 3rd trimester. Of the eight patients with active HBV, six were successfully treated post-partum with oral antivirals/PEG-Interferon and two became inactive. 20% of inactive carriers experienced a post-partum flare in ALT that settled spontaneously. <h3>Conclusion</h3> A high proportion of HBV infected mothers were born overseas; &gt;1 in 6 had active cHBV or HBV DNA &gt;10<sup>7</sup> IU/ml and were eligible for treatment to reduce the vertical transmission risk and/or prevent disease progression. All HBV infected mothers should be assessed for treatment and efforts to improve attendance at clinic appointments need to be intensified. <h3>Competing interests</h3> None declared.
German insurer finds a third of people over 65 take five or more drugs a day
Authors: N. Stafford
Journal: BMJ (2013)

Germany’s senior citizens are taking too many prescription drugs while the number of children and young people being prescribed antipsychotic drugs has risen sharply since 2005 for no apparent medical reason, a report has found. 

The annual pharmaceutical report, commissioned by Barmer GEK—one of Germany’s largest public health insurers—is based on prescriptions and diagnoses in 2012 for 9.1 million people insured through Barmer.1

It found that 33% of the 2.1 million people it insured over the age of 65 took five or more prescription drugs each day, while 11% took eight or more per day. Barmer, which spent nearly €4bn (£3.4bn; $5.3bn) …
AB0277 Antinuclear antibodies in patients with tnf- inhibitors
Authors: J. Eibl, W. Klotz, M. Herold
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> During treatment of patients with rheumatic disease like rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriatic arthritis (PsA) with anti TNF-α antibodies (TNF-inhibitors) induction of antinuclear antibodies (ANA) may occur. <h3>Objectives</h3> This study is a retrospective examination, to evaluate the number of patients treated with TNF-inhibitors and developing ANAs during treatment. <h3>Methods</h3> In a retrospective case-control-study 117 patients were selected, all of whom had received anti TNF-α therapy for at least 6 months. ANA titers were measured by indirect immunofluorescence using HEp-2 cells. Patients were included with clinical diagnosis of RA (n=83), PsA (n=8), and SpA (n=26) respectively. <h3>Results</h3> 24 patients were found with ANA titers &gt;1:100 before anti-TNF treatment and excluded from further testing. This occurred primarily in patients diagnosed with RA (n=22), and was seen only in one patient with PsA and one with SpA. Among the remaining 93 patients, 31 showed a rise in ANA titer (either from negative to titer &gt;1:100 or at least two titer steps) during anti TNF-α treatment, 19 of them were diagnosed RA (22.9 %), 3 PsA (37.5 %) and 9 SpA (34.6 %). HEp-2 patterns were classified as homogenous (n=20, 64.5 %), mixed homogenous &amp; fine speckled (n=8, 25.8 %), fine speckled (n=2, 6.4 %) and nucleolar (n=1, 3.2 %). Median time between start of treatment and occurrence of ANA titers was 33 weeks, with a minimum of 4 and a maximum of 308 weeks. All TNF-inhibitors available in Austria were used (Adalimumab, n=42; Etanercept, n=29; Inflixmab, n=28; Golimumab, n=8; Certolizumab, n=1). ANA were induced in 15 patients treated with Infliximab (53.6 %), 13 treated with Adalimumab (31.0 %), one with Etanercept (3.4 %), one with Golimumab (12.5%) and in the single patient treated with Certolizumab. 13 patients with positive ANA titers were switched to a biological other than TNF-inhibitor. 10 times of which the patients retained ANA titers. One patient showed decreasing titers after changing the drug, but increased again after some time, and two patients showed decreasing ANA titers. <h3>Conclusions</h3> Incidence and increase of ANA titers during anti-TNF-treatment is similar in patients with different diseases (RA, SpA, PsA), but there seems to be a different incidence among TNF-inhibitors. <h3>Disclosure of Interest</h3> None Declared
Abstract 1951: Inhibition of aurora kinase using VX-680 enhances the radiation response in glioma cells
Authors: Esther P. Jane, Daniel R. Premkumar, Ian F. Pollack
Journal: Cancer Research (2011)

Abstract The central role of aurora kinases in cell cycle regulation coupled with overexpression of aurora A and B kinases in a wide variety of human malignancies that led to the development of pharmacological inhibitors of aurora kinases. New generations of aurora inhibitors, including VX-680, has been evaluated preclinically and are in phase I and II trials for the treatment of solid tumors and leukemia. In this study, we investigated the role of VX680, Aurora kinase inhibitor in malignant human glioma cells with different p53 statuses as well as cytotoxicity of glioma cells to irradiation. VX-680 inhibits aurora A and B kinases and cell proliferation with nanomolar to low micromolar potency. Endoreduplication, the re-replication of DNA in the absence of mitotic division, ultimately results in polyploidy and inhibition of cell proliferation. VX680 treatment led to an increase in the number of multinucleated cells and the ratios of G2/M phase in p53-mutant (LN229) and p53-deleted cells (LNZ308), but minimal in p53-wild type (A172) glioma cells. FACS analysis revealed that the increase in nuclear size correlated with polyploidization, reaching a &amp;gt;16 DNA content on day 2. During mitosis, the cells rounded normally, condensed their chromosomes on a metaphase-like plate. Our results demonstrate that pretreating cells with VX-680 prior to ionizing radiation led to an enhancement of radiation -induced apoptosis. Accordingly, our results suggested that Aurora kinase inhibition followed by irradiation increases in the appearance of multinucleated cells and increase apoptosis, and this treatment may become a potential therapy against malignant human gliomas. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1951. doi:10.1158/1538-7445.AM2011-1951
FRI0298 Differences between juvenile and adult-onset ankylosing spondylitis in moroccan patients
Authors: Y. Ibn Yacoub, B. Amine, A. Laatiris, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> We aimed to assess differences between juvenile-onset ankylosing spondylitis (JOAS) and adult-onset ankylosing spondylitis (AOAS) in terms of activity, severity and quality of life (QoL) in Moroccan patients. <h3>Methods</h3> In this cross-sectional study, 120 patients with ankylosing spondylitis according to the modified New York classification criteria were consecutively recruited. JOAS was defined as an age at onset ≤16 years-old and AOAS &gt;16 years-old. Assessment criteria included: sociodemographic data, educational level, diagnosis delay, peripheral and axial pain (on a visual analogue scale), disease activity (Bath Ankylosing Spondylitis Disease Activity index), functional impairment (Bath Ankylosing Spondylitis Functional Index), spinal mobility (Bath Ankylosing Spondylitis Metrology Index); structural damage (Bath Ankylosing Spondylitis Radiologic Index) and treatment details. The Maastricht Ankylosing Spondylitis Enthesis Score (MASES) was applied to assess severity of enthesitis. Laboratory tests included the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP). The generic instrument SF-36 was used to assess QoL. Comparisons were examined using a T test for continuous variables and Chi-square test for categorical variables. Logistic regression models were used to assess associations between JOAS and disease parameters. <h3>Results</h3> In our data, 37 patients (30.8%) had JOAS and 83 (69.1%) had AOAS. There were no differences between the two groups according to gender, socioeconomic status, diagnosis delay, treatments, structural damage (BASRI) or scores of spinal mobility. However, patients with JOAS had more severe peripheral pain intensity, higher clinical and biological disease activity (BASDAI and CRP), severe enthesitis scores; impaired functional ability and more prevalent hip involvement (for all p≤0.001). Moreover, patients with JOAS had lower educational level (p=0.014) and significantly lower scores of physical domains of QoL (for all p≤0.01). In logistic regression, JOAS was associated with severe peripheral pain [OR =1.391-CI (95%) 0.514-0.983], higher enthesitis scores [OR =1.522-CI (95%) 1.074-1.864] and severe functional disability [OR =1.517-CI (95%) 1.108-1.754]. <h3>Conclusions</h3> In our study, we state that our AS patients presented differently according to the age at onset. Patients with JOAS had altered aspects of QoL with more peripheral and entheseal involvement, high disease activity an altered functional ability. An early diagnosis and treatment of AS, particularly JOAS seem to be important in order to improve patients’ living and quality of life. <h3>Disclosure of Interest</h3> None Declared